Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EN-RX1
- Development stage
- Preclinical
- Lead developer
- Enedra Therapeutics
01
Overview
EN-RX1 is a preclinical-stage precision medicine candidate being developed by Enedra Therapeutics for the treatment of solid tumours. Discovered using the AI-driven CASPAROV™ platform, the program targets genetically heterogeneous cancers driven by chromosomal instability. EN-RX1 aims to exploit novel essential survival mechanisms specific to cancer cells, utilizing proprietary Convergent Genomic Signatures (CGS) for precise patient stratification. While the specific molecular target and modality (e.g., small molecule or biologic) have not been publicly disclosed, the program is currently at the candidate stage of preclinical development.
Beyond the preview
Go deeper on EN-RX1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EN-RX1.